Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03610932
Other study ID # STUDY00140641
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date July 1, 2018
Est. completion date May 3, 2019

Study information

Verified date December 2019
Source University of Kansas Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research is to assess the association between diet and pulmonary function during standardized EIB testing. Determine the effect of Vitamin C supplementation on airway inflammatory markers and bronchoconstriction after a standardized EIB test compared to usual diet and placebo control.


Description:

This study will use a double-blind, randomized, cross-over design with subjects serving as their own controls. This study will be conducted over a consecutive five-week period.

All subjects will be asked to discontinue taking their short- and long-acting beta-agonist medication 12 and 24 hours respectively prior to data collection. Also, all subjects will be asked to refrain from caffeine, physical activity, and NSAID use 24 hours prior to testing. In addition all subjects will be asked to abstain from taking any vitamin supplement during the course of the study.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 3, 2019
Est. primary completion date May 3, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Student or student-athlete who has tested positive for EIB

- Able to communicate in English

Exclusion Criteria:

- Forced expiratory volume in 1 second (FEV1) < 70% of predicted, cardiac history,

- Current respiratory infection

- > 10 pack year history of smoking

- Pregnancy.

Study Design


Intervention

Dietary Supplement:
Vitamin C
Taken as 3 500mg capsules.
Other:
Placebo
Taken as 3 500mg capsules.

Locations

Country Name City State
United States University of Kansas Medical Center Kansas City Kansas

Sponsors (1)

Lead Sponsor Collaborator
University of Kansas Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in airway inflammatory biomarkers Urinary concentrations of cysteine leukotrienes (LTC4-LTE4), prostaglandin (9a,11ß-PGF2), and creatinine will be measured. Change from Baseline to End of Week 5
Secondary Change in quality of life: asthma quality of life questionnaire (AQLQ) Asthma specific quality of life will be measured by the validated asthma quality of life questionnaire (AQLQ). The AQLQ includes 32 separate responses within 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). Each response option is based on a 7-point scale, where 1 represents maximal impairment and 7 indicates no impairment. Scores for the four domains and overall score are computed as averages of the item scores. The minimal important difference for overall and each domain, has been determined to be a change in score of 0.5 per item. Change from Baseline to End of Week 5
Secondary Dietary Intake Questionnaire Baseline dietary intake will be assessed by the National Cancer Institute's Diet Health Questionnaire II (DHQ II). It consists of 134 food items and 8 dietary supplement questions. It calculates the Healthy Eating Index (HEI) that is a measure of diet quality. Scores range from 0 to 100. The higher the score the healthier the diet. Change from Baseline to End of Week 5
Secondary Cardiorespiratory Fitness Cardiorespiratory fitness will be assessed during the EIB test by an integrated metabolic measurement system that will be used for measurement of oxygen consumption. The metabolic cart will be set to produce a 15-second average of the data collected during gas analyses for all tests. Baseline
Secondary Pulmonary function testing The outcome will measure the change in the first second of forced expiration (FEV1). Change from Baseline to End of Week 5
See also
  Status Clinical Trial Phase
Withdrawn NCT00375232 - Effects of Montelukast on Occult Exercise-Induced Bronchospasm in Athletes N/A
Completed NCT00085774 - Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma Phase 3
Completed NCT00268723 - Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB Phase 3
Completed NCT00701025 - Mechanisms of Exercise-induced Bronchospasm
Withdrawn NCT00662779 - Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB) Phase 3